We Think Bioceltix (WSE:BCX) Can Afford To Drive Business Growth
Dec 11
Have your own idea? Try our Stock Screener
Polish (WIG) Biotech Industry Analysis
UpdatedJan 16, 2026
DataAggregated Company Financials
Companies13
- 7D1.2%
- 3M4.9%
- 1Y2.3%
- YTD5.7%
Last week, the Biotech industry hasn't moved much but Bioceltix is up 5.6% in that time. Furthermore, the industry has been flat for the past year as well. Earnings are forecast to grow by 57% annually.
Industry Valuation and Performance
Has the Polish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 16 Jan 2026 | zł2.0b | zł427.5m | -zł155,672,238.00 | 45x | -13x | 4.7x |
| Sun, 14 Dec 2025 | zł1.8b | zł427.5m | -zł155,672,238.00 | 44.7x | -11.8x | 4.3x |
| Tue, 11 Nov 2025 | zł1.9b | zł425.3m | -zł159,129,765.00 | 46.2x | -12x | 4.5x |
| Thu, 09 Oct 2025 | zł2.0b | zł394.3m | -zł169,922,766.00 | 40.7x | -11.5x | 4.9x |
| Sat, 06 Sep 2025 | zł1.9b | zł403.5m | -zł140,003,812.00 | 43.4x | -13.7x | 4.7x |
| Mon, 04 Aug 2025 | zł2.1b | zł401.8m | -zł140,766,468.00 | 31.6x | -14.6x | 5.1x |
| Wed, 02 Jul 2025 | zł2.0b | zł401.8m | -zł140,766,468.00 | 33.2x | -14.4x | 5x |
| Fri, 30 May 2025 | zł2.0b | zł398.0m | -zł143,232,373.00 | 48.5x | -14.1x | 5.1x |
| Sun, 27 Apr 2025 | zł2.0b | zł438.6m | -zł95,762,193.00 | 28.4x | -21x | 4.6x |
| Tue, 25 Mar 2025 | zł2.0b | zł438.8m | -zł95,426,193.00 | 31x | -20.9x | 4.6x |
| Thu, 20 Feb 2025 | zł2.1b | zł438.8m | -zł94,289,269.00 | 42.2x | -21.7x | 4.7x |
| Sat, 18 Jan 2025 | zł1.9b | zł408.7m | -zł84,434,269.00 | 43.4x | -22.6x | 4.7x |
| Mon, 16 Dec 2024 | zł1.9b | zł408.7m | -zł84,434,269.00 | 38.3x | -22.3x | 4.6x |
| Wed, 13 Nov 2024 | zł2.0b | zł401.6m | -zł85,417,969.00 | 58.8x | -23.8x | 5.1x |
| Fri, 11 Oct 2024 | zł2.2b | zł438.7m | -zł64,845,969.00 | 62.4x | -33.2x | 4.9x |
| Sun, 08 Sep 2024 | zł2.2b | zł449.1m | -zł48,500,784.00 | 64.6x | -45.2x | 4.9x |
| Tue, 06 Aug 2024 | zł2.0b | zł444.2m | -zł64,230,755.00 | 71x | -31.8x | 4.6x |
| Thu, 04 Jul 2024 | zł2.0b | zł444.2m | -zł64,230,755.00 | 71x | -31.3x | 4.5x |
| Sat, 01 Jun 2024 | zł2.2b | zł439.7m | -zł97,717,228.00 | 71x | -22.4x | 5x |
| Mon, 29 Apr 2024 | zł2.3b | zł441.3m | -zł93,380,007.00 | 56x | -24.1x | 5.1x |
| Wed, 27 Mar 2024 | zł2.2b | zł462.1m | -zł74,341,007.00 | 59.1x | -29.2x | 4.7x |
| Fri, 23 Feb 2024 | zł2.4b | zł462.1m | -zł74,341,007.00 | 60.1x | -31.8x | 5.1x |
| Sun, 21 Jan 2024 | zł2.7b | zł499.9m | -zł66,755,911.00 | 88.7x | -40.6x | 5.4x |
| Tue, 19 Dec 2023 | zł2.8b | zł499.9m | -zł66,755,911.00 | 92.5x | -41.6x | 5.6x |
| Thu, 16 Nov 2023 | zł2.6b | zł511.7m | -zł63,340,678.00 | 45.3x | -41.2x | 5.1x |
| Sat, 14 Oct 2023 | zł2.6b | zł518.4m | -zł60,859,678.00 | 48.6x | -43.2x | 5.1x |
| Mon, 11 Sep 2023 | zł2.9b | zł522.2m | -zł66,814,668.00 | 49.6x | -42.7x | 5.5x |
| Wed, 09 Aug 2023 | zł2.8b | zł520.7m | -zł42,515,291.00 | 51.2x | -66.3x | 5.4x |
| Fri, 07 Jul 2023 | zł2.8b | zł520.7m | -zł42,515,291.00 | 51.9x | -65.2x | 5.3x |
| Sun, 04 Jun 2023 | zł2.9b | zł516.4m | -zł51,576,721.00 | 63.7x | -55.6x | 5.6x |
| Tue, 02 May 2023 | zł2.9b | zł536.5m | -zł32,904,449.00 | 68.2x | -89.3x | 5.5x |
| Thu, 30 Mar 2023 | zł2.7b | zł488.3m | -zł16,018,449.00 | 56.8x | -170.4x | 5.6x |
| Sat, 25 Feb 2023 | zł2.9b | zł488.6m | -zł16,165,349.00 | 67x | -180.7x | 6x |
| Mon, 23 Jan 2023 | zł3.0b | zł496.5m | -zł10,783,764.00 | 47.8x | -275x | 6x |
Price to Earnings Ratio
-275x
Current Industry PE
- Investors are relatively neutral on the Polish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 4.9% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the Polish Healthcare industry?
| PL Market | 1.51% | |
| Healthcare | 2.71% | |
| Biotech | 1.21% | |
| Biotech | 1.21% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BCX Bioceltix | zł82.70 | 6.3% +zł24.1m | -1.8% | PB15.1x | |
| MAB Mabion | zł8.40 | 5.3% +zł6.8m | -10.9% | PS9.2x | |
| PTG Poltreg | zł26.40 | 3.5% +zł4.2m | -29.8% | PB2.5x | |
| URT Urteste | zł45.60 | 1.8% +zł1.1m | -53.0% | PS35.7x | |
| GMT Genomtec | zł3.90 | 0.4% +zł226.0k | -47.4% | PS3911.8x |